Search Results

There are 11141 results for: content related to: Geographic information systems and pharmacoepidemiology: using spatial cluster detection to monitor local patterns of prescription opioid abuse

  1. Illicit Use of Opioids: Is OxyContin® a “Gateway Drug”?

    The American Journal on Addictions

    Volume 16, Issue 3, May-June 2007, Pages: 166–173, Lauretta E. Grau PhD, Nabarun Dasgupta MPH, Alison Phinney Harvey MPH, Kevin Irwin MA, Anthony Givens, Mark L. Kinzly and Robert Heimer PhD

    Version of Record online : 19 APR 2010, DOI: 10.1080/10550490701375293

  2. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program

    Pharmacoepidemiology and Drug Safety

    Volume 26, Issue 9, September 2017, Pages: 1044–1052, Suzanne K. Vosburg, Colleen Haynes, Andrea Besharat and Jody L. Green

    Version of Record online : 27 JUN 2017, DOI: 10.1002/pds.4248

  3. Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007

    Pharmacoepidemiology and Drug Safety

    Volume 18, Issue 9, September 2009, Pages: 778–790, Michael F. Schneider, J. Elise Bailey, Theodore J. Cicero, Richard C. Dart, James A. Inciardi, Mark Parrino and Alvaro Muñoz

    Version of Record online : 17 JUN 2009, DOI: 10.1002/pds.1780

  4. Impact of abuse-deterrent OxyContin on prescription opioid utilization

    Pharmacoepidemiology and Drug Safety

    Volume 24, Issue 2, February 2015, Pages: 197–204, Catherine S. Hwang, Hsien-Yen Chang and G. Caleb Alexander

    Version of Record online : 13 NOV 2014, DOI: 10.1002/pds.3723

  5. National addictions vigilance intervention and prevention program (NAVIPPRO™): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse

    Pharmacoepidemiology and Drug Safety

    Volume 17, Issue 12, December 2008, Pages: 1142–1154, Stephen F. Butler, Simon H. Budman, Andrea Licari, Theresa A. Cassidy, Katherine Lioy, James Dickinson, John S. Brownstein, James C. Benneyan, Traci Craig Green and Nathaniel Katz

    Version of Record online : 17 OCT 2008, DOI: 10.1002/pds.1659

  6. Abstracts

    Pharmacoepidemiology and Drug Safety

    Volume 20, Issue S1, August 2011, Pages: S1–S364,

    Version of Record online : 12 AUG 2011, DOI: 10.1002/pds.2206

  7. Pharmacokinetics of Intranasal Crushed OxyContin and Intravenous Oxycodone in Nondependent Prescription Opioid Abusers

    The Journal of Clinical Pharmacology

    Volume 52, Issue 4, April 2012, Pages: 600–606, Dr M. R. Lofwall, Dr D. E. Moody, Dr W. B. Fang, Mr. P. A. Nuzzo and Dr S. L. Walsh

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270011401620

  8. You have full text access to this OnlineOpen article
    The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting

    Clinical Pharmacology & Therapeutics

    Volume 100, Issue 3, September 2016, Pages: 275–286, PM Coplan, HD Chilcoat, SF Butler, EM Sellers, A Kadakia, V Harikrishnan, JD Haddox and RC Dart

    Version of Record online : 22 JUN 2016, DOI: 10.1002/cpt.390

  9. Changes in Prevalence of Prescription Opioid Abuse after Introduction of an Abuse-Deterrent Opioid Formulation

    Pain Medicine

    Volume 15, Issue 3, March 2014, Pages: 440–451, Theresa A. Cassidy, Pronabesh DasMahapatra, Ryan A. Black, Matthew S. Wieman and Stephen F. Butler

    Version of Record online : 11 DEC 2013, DOI: 10.1111/pme.12295

  10. You have free access to this content
    Abstracts

    Pharmacoepidemiology and Drug Safety

    Volume 24, Issue S1, September 2015, Pages: 1–587,

    Version of Record online : 25 SEP 2015, DOI: 10.1002/pds.3838

  11. You have full text access to this OnlineOpen article
    Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics

    Pharmacoepidemiology and Drug Safety

    Volume 22, Issue 12, December 2013, Pages: 1274–1282, Paul M. Coplan, Hrishikesh Kale, Lauren Sandstrom, Craig Landau and Howard D. Chilcoat

    Version of Record online : 30 SEP 2013, DOI: 10.1002/pds.3522

  12. You have full text access to this OnlineOpen article
    Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation

    Pharmacoepidemiology and Drug Safety

    Volume 23, Issue 12, December 2014, Pages: 1238–1246, Nelson E. Sessler, Jerod M. Downing, Hrishikesh Kale, Howard D. Chilcoat, Todd F. Baumgartner and Paul M. Coplan

    Version of Record online : 11 JUN 2014, DOI: 10.1002/pds.3658

  13. Risk Evaluation and Mitigation Strategies for Drugs with Abuse Liability

    Annals of the New York Academy of Sciences

    Volume 1141, Issue 1, October 2008, Pages: 284–303, Curtis Wright IV, Sidney Schnoll and David Bernstein

    Version of Record online : 23 OCT 2008, DOI: 10.1196/annals.1441.026

  14. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis

    Addiction

    Volume 107, Issue 3, March 2012, Pages: 587–596, April M. Young and Jennifer R. Havens

    Version of Record online : 26 OCT 2011, DOI: 10.1111/j.1360-0443.2011.03635.x

  15. Prescription Opioid Abuse and Dependence: Assessment Strategies for Counselors

    Journal of Counseling & Development

    Volume 85, Issue 2, Spring 2007, Pages: 211–215, Daniel J. Weigel, Kimberly A. Donovan, Kevin S. Krug and Wayne A. Dixon

    Version of Record online : 23 DEC 2011, DOI: 10.1002/j.1556-6678.2007.tb00465.x

  16. FROM WHITE BULLETS TO BLACK MARKETS AND GREENED MEDICINE: THE NEUROECONOMICS AND NEURORACIAL POLITICS OF OPIOID PHARMACEUTICALS

    Annals of Anthropological Practice

    Volume 36, Issue 1, May 2012, Pages: 167–182, Helena Hansen and Mary E. Skinner

    Version of Record online : 19 SEP 2012, DOI: 10.1111/j.2153-9588.2012.01098.x

  17. FDA approves OxyContin for certain pediatric patients

    Alcoholism & Drug Abuse Weekly

    Volume 27, Issue 36, 21 September 2015, Pages: 4–5, Alison Knopf

    Version of Record online : 21 SEP 2015, DOI: 10.1002/adaw.30322

  18. AAPM 2015 ANNUAL MEETING ABSTRACTS

    Pain Medicine

    Volume 16, Issue 3, March 2015, Pages: 558–622,

    Version of Record online : 19 MAR 2015, DOI: 10.1111/pme.12696

  19. You have free access to this content
    Tapentadol Abuse Potential: A Postmarketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse Treatment

    Pain Medicine

    Volume 16, Issue 1, January 2015, Pages: 119–130, Stephen F. Butler, Emily C. McNaughton and Ryan A. Black

    Version of Record online : 22 SEP 2014, DOI: 10.1111/pme.12524

  20. Study finds heroin deaths rose as Rx opioid deaths declined

    Alcoholism & Drug Abuse Weekly

    Volume 27, Issue 6, 9 February 2015, Pages: 3–5, Alison Knopf

    Version of Record online : 6 FEB 2015, DOI: 10.1002/adaw.30069